文献速递前列腺癌

将风险分层的早期前列腺癌检测转向初级医疗保健机构

Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
PubMed 文献 · BJU Int · 2022-12-19

该观察性研究在荷兰鹿特丹的初级医疗保健诊断机构STAR-SHL开展,全科医生可将希望接受前列腺癌筛查的男性转诊至该机构,由受过专门培训的人员进行咨询,并依据鹿特丹前列腺癌风险计算器(RPCRC)的结果决定是否转诊至二级医疗,再与现行荷兰全科医生PSA转诊阈值3.0 ng/mL进行比较。2014年1月至2021年2月共507名男性被转诊咨询,495人检测了PSA。研究结论认为,与PSA阈值3.0 ng/mL相比,RPCRC可减少最多68%的二级医疗转诊,并在接受活检的男性中带来较高的临床显著前列腺癌检出率。

要点

  • 在初级医疗诊断机构中,RPCRC较PSA阈值3.0 ng/mL可减少最多68%的二级医疗转诊。
  • 279名PSA≥3.0 ng/mL的男性中,68%(95%CI 63-74)被RPCRC判为低风险。
  • 低风险男性1年内临床显著前列腺癌诊断比例为0.52%(95%CI 0.092-2.9),此后又有2.1%(95%CI 0.82-5.3)被诊断为临床显著前列腺癌。

核心结论

  • 在初级医疗保健诊断机构中,RPCRC与PSA转诊阈值3.0 ng/mL相比可减少最多68%的二级医疗转诊。
  • 在此环境中应用RPCRC使接受活检的男性中获得较高的临床显著前列腺癌检出率。
  • 作者认为该策略可被视为安全,因为观察数据显示低风险男性中临床显著前列腺癌比例较低。

研究设计与样本

  • 这是一项观察性研究,由Erasmus MC Cancer Institute与位于鹿特丹市中心的初级医疗保健诊断机构STAR-SHL于2014年发起。
  • 全科医生可将希望接受前列腺癌筛查的男性转诊至STAR-SHL,由受过专门培训的人员进行咨询。
  • 是否转诊至二级医疗依据鹿特丹前列腺癌风险计算器(RPCRC)的结果,并与现行荷兰全科医生PSA转诊阈值3.0 ng/mL进行比较。
  • 研究队列与荷兰全国病理数据库(PALGA)链接以收集前列腺癌诊断数据。
  • 2014年1月至2021年2月共507名男性被转诊咨询,其中495人检测了PSA;从咨询到PALGA链接的中位随访时间为43个月(四分位距25-65)。

主要发现

  • 507名被转诊咨询的男性中,495人检测了PSA。
  • 279名男性(56%)PSA水平≥3.0 ng/mL,其中68%(95%CI 63-74)按RPCRC被认为处于低风险。
  • 低风险男性中,咨询后1年内有1人(0.52%;95%CI 0.092-2.9)被诊断为临床显著前列腺癌(即国际泌尿病理学会分级分组≥2)。
  • 此后另有4名低风险男性(2.1%;95%CI 0.82-5.3)被诊断为临床显著前列腺癌。
  • 咨询后1年内接受活检的高风险男性(n=61)中,77%(95%CI 65-86)被诊断为前列腺癌,49%(95%CI 37-61)被诊断为临床显著前列腺癌。

临床怎么用

  • 作者认为,在初级医疗保健诊断机构中应用RPCRC可减少最多68%的二级医疗转诊。
  • 作者认为该策略可被视为安全,依据是观察数据显示低风险男性中临床显著前列腺癌比例较低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the feasibility of multivariable risk stratification for early prostate cancer (PCa) detection in a primary healthcare diagnostic facility with regard to its effects on the referral rate and subsequent PCa diagnoses compared to a PSA threshold of 3.0 ng/mL as the current referral indicator. PATIENTS AND METHODS: In 2014, the Erasmus MC Cancer Institute and the primary healthcare diagnostic facility STAR-SHL (located in Rotterdam city centre) initiated this observational study, in which general practitioners (GPs) could refer men who wished to undergo PCa screening to STAR-SHL for consultation by specially trained personnel. Referral recommendations to secondary healthcare were based on the outcome of application of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and were compared to the current Dutch GPs' PSA referral threshold of 3.0 ng/mL. For data collection on PCa diagnoses, the study cohort was linked to the Dutch nationwide pathology databank (PALGA). RESULTS: Between January 2014 and February 2021, 507 men were referred for consultation and in 495 men prostate-specific antigen (PSA) was tested. The median (interquartile range) follow-up from consultation to PALGA linkage was 43 (25-65) months. In total, 279 men (56%) had a PSA level ≥3.0 ng/mL, of whom 68% (95% confidence interval [95% CI] 63-74) were considered at low risk according to the RPCRC. Within 1 year after consultation, one of these men (0.52%; 95% CI 0.092-2.9) was diagnosed with clinically significant (cs)PCa (i.e., International Society of Urological Pathology Grade Group ≥2). Thereafter, another four (2.1%; 95% CI 0.82-5.3) low-risk men were diagnosed with csPCa. Of the high-risk men who were biopsied within 1 year after consultation (n = 61), 77% (95% CI 65-86) were diagnosed with PCa and 49% (95% CI 37-61) with csPCa. CONCLUSION: In a primary healthcare diagnostic facility, the RPCRC could reduce up to 68% of referrals to secondary healthcare, as compared to a PSA referral threshold of 3.0 ng/mL. Deploying the RPCRC in this setting resulted in a high csPCa detection rate in those men biopsied. This strategy can be considered safe since the observational data showed low proportions of csPCa among men at low risk.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hogenhout R, Osses DF, Alberts AR, et al. Shifting risk-stratified early prostate cancer detection to a primary healthcare setting. BJU Int. 2022. PMID: 36408660. doi:10.1111/bju.15933

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。